JPWO2022080486A1 - - Google Patents

Info

Publication number
JPWO2022080486A1
JPWO2022080486A1 JP2022557482A JP2022557482A JPWO2022080486A1 JP WO2022080486 A1 JPWO2022080486 A1 JP WO2022080486A1 JP 2022557482 A JP2022557482 A JP 2022557482A JP 2022557482 A JP2022557482 A JP 2022557482A JP WO2022080486 A1 JPWO2022080486 A1 JP WO2022080486A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557482A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022080486A1 publication Critical patent/JPWO2022080486A1/ja
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/375Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
JP2022557482A 2020-10-16 2021-10-15 Pending JPWO2022080486A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020174961 2020-10-16
PCT/JP2021/038254 WO2022080486A1 (ja) 2020-10-16 2021-10-15 ポリペプチド、多量体、固相、被検物質の測定方法および試薬キット

Publications (1)

Publication Number Publication Date
JPWO2022080486A1 true JPWO2022080486A1 (https=) 2022-04-21

Family

ID=81208108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557482A Pending JPWO2022080486A1 (https=) 2020-10-16 2021-10-15

Country Status (5)

Country Link
US (1) US20230288411A1 (https=)
EP (1) EP4230643A4 (https=)
JP (1) JPWO2022080486A1 (https=)
CN (1) CN116348498A (https=)
WO (1) WO2022080486A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023132075A (ja) * 2022-03-10 2023-09-22 シスメックス株式会社 L-ビオチン測定用試薬、l-ビオチンを含む試料の測定方法、l-ビオチン標識された物質の標識数の決定方法、及び光学異性アビジン類が固定化された固相の製造方法
EP4522281A2 (en) * 2022-05-13 2025-03-19 University of Utah Research Foundation Biotin orthogonal streptavidin system

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07289264A (ja) * 1994-04-27 1995-11-07 Kikkoman Corp 変異型ストレプトアビジン遺伝子、変異型ストレプトアビジン−ホタルルシフェラーゼ融合蛋白質遺伝子、新規な組み換え体dna及びストレプトアビジン−ホタルルシフェラーゼ融合蛋白質の製造法
JPH09506106A (ja) * 1993-12-07 1997-06-17 ネオルクス コーポレーション プレターゲティング方法及び化合物
JPH1010359A (ja) * 1996-06-21 1998-01-16 Ando Electric Co Ltd 光結合器
JP2004357568A (ja) * 2003-06-04 2004-12-24 National Food Research Institute アビジンをコードする人工合成遺伝子
WO2011158798A1 (ja) * 2010-06-14 2011-12-22 国立大学法人山口大学 乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット
WO2013018836A1 (ja) * 2011-08-01 2013-02-07 日本たばこ産業株式会社 生物学的試料中の物質を検出する工程において、非特異的結合を抑制する方法、当該方法に使用するための剤
WO2019188297A1 (ja) * 2018-03-30 2019-10-03 シスメックス株式会社 リポタンパク質の取り込み能を測定する方法及び試薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2606722B2 (ja) 1988-04-05 1997-05-07 栄治 石川 超高感度抗原物質の測定法
EP0977770A4 (en) * 1997-03-14 2000-04-05 Univ Boston DIFFERENTLY FLAVORED STREPTAVIDINE
EP1369476B1 (en) 2001-03-12 2010-07-21 Japan Tobacco Inc. A novel protein, a gene encoding therefor and a method of using the same
WO2006058226A2 (en) 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
GB0919102D0 (en) * 2009-10-30 2009-12-16 Isis Innovation Streptavidin mutant proteins
RU2013111677A (ru) * 2010-08-30 2014-10-10 Ф. Хоффманн-Ля Рош Аг Конструкция для экспрессии у прокариот
JP6178586B2 (ja) * 2013-02-20 2017-08-09 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
JP7339160B2 (ja) * 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506106A (ja) * 1993-12-07 1997-06-17 ネオルクス コーポレーション プレターゲティング方法及び化合物
JPH07289264A (ja) * 1994-04-27 1995-11-07 Kikkoman Corp 変異型ストレプトアビジン遺伝子、変異型ストレプトアビジン−ホタルルシフェラーゼ融合蛋白質遺伝子、新規な組み換え体dna及びストレプトアビジン−ホタルルシフェラーゼ融合蛋白質の製造法
JPH1010359A (ja) * 1996-06-21 1998-01-16 Ando Electric Co Ltd 光結合器
JP2004357568A (ja) * 2003-06-04 2004-12-24 National Food Research Institute アビジンをコードする人工合成遺伝子
WO2011158798A1 (ja) * 2010-06-14 2011-12-22 国立大学法人山口大学 乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット
WO2013018836A1 (ja) * 2011-08-01 2013-02-07 日本たばこ産業株式会社 生物学的試料中の物質を検出する工程において、非特異的結合を抑制する方法、当該方法に使用するための剤
US20140242620A1 (en) * 2011-08-01 2014-08-28 Japan Tobacco Inc. Method of inhibiting non-specific binding in step of detecting substance in biological sample, and agent for use in the method
WO2019188297A1 (ja) * 2018-03-30 2019-10-03 シスメックス株式会社 リポタンパク質の取り込み能を測定する方法及び試薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 22, JPN6021048672, 2014, pages 56 - 61, ISSN: 0005727806 *

Also Published As

Publication number Publication date
WO2022080486A1 (ja) 2022-04-21
EP4230643A1 (en) 2023-08-23
CN116348498A (zh) 2023-06-27
US20230288411A1 (en) 2023-09-14
EP4230643A4 (en) 2025-04-02

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240925

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241031

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417